摘要
目的:探讨血清高尔基体糖蛋白73(GP73)在原发性肝癌患者中的临床应用价值。方法:收集肝癌实验组患者53例、肝病对照组患者88例、肝癌复发监测组患者8例、肝癌疗效观察组13例和健康对照组20例血清,采用酶联免疫吸附试验(ELISA)定量检测法测定血清GP73的浓度,7600生化分析仪测定血清谷丙转氨酶(ALT)、直接胆红素(DBIL)、总胆汗酸(TBA)的水平。结果:肝癌实验组血清GP73水平高于肝病对照组及健康对照组,差异具有统计学意义(P<0.05);血清GP73水平分别与ALT、DBIL、TBA水平高度相关,差异具有统计学意义(P<0.05);血清GP73水平与门脉癌栓的发生相关,差异具有统计学意义(P<0.05);肝癌疗效观察组有3例血清GP73浓度随着有效治疗下降;肝癌复发监测组8例GP73随着肿瘤复发而上升,差异具有统计学意义(P<0.05)。结论:血清GP73可作为反映原发性肝癌患者肝损伤的血清指标,对原发性肝癌的辅助诊断、疗效观察、预后判断、复发监测具有临床意义。
Objective：To explore the clinical value of serum GP73level in patients with primary hepatocellular carcinoma.Methods：A total of 53liver cancer patients（experimental group,n=53cases） and 88cases of liver disease（control group,n=88cases）,8cases with hepatoma relapse under monitoring（monitoring group,n=13cases）and 13liver cancer patients under curative effect observation group as well as 20healthy volunteers（healthy control group）were collected.The quantitative detection of GP73 were determined with enzyme-linked immunosorbent assay（ELISA）,serum concentrations of ALT,DBIL and TBA were detected with 7600biochemical analyzer.Results：1.Serum GP73level in patients with liver cancer in experimental group was significantly higher than that in control group and healthy control group（P0.05）.2.Serum GP73level was highly correlated with ALT,DBIL,TBA levels（P0.05）.3.The serum GP73level was related to the occurance of portal vein tumor thrombus（P0.05）.4.Serum GP73 concentration in 3cases of the 13liver cancer patients under curative effect observation group decreased with the degree of cure effects,and increased with the relapse of hepatocellular carcinoma（P0.05）. Conclusions：Serum GP73can be used as the serum indicator which reflects the primary liver damage in the patients with hepatocellular carcinoma,and has clinical significance for auxilliary diagnosis,observation of curative effect,prognosis,and relapse monitoring of primary hepatocellular carcinoma.
出处
《海南医学院学报》
CAS
2014年第1期83-86,89,共5页
Journal of Hainan Medical University
基金
广州市市科技计划项目(18239430)~~
